Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Breast Neoplasms 5Brain Neoplasms 5Glioblastoma 3Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1

Interventions

Radiosurgery 8Docetaxel 4Cisplatin 4Carboplatin 4Magnetic Resonance Spectroscopy 3Filgrastim 3pembrolizumab 2Specimen Handling 2Radiotherapy 2Paclitaxel 2Nivolumab 2Mental Status and Dementia Tests 2Memantine 2Fluorodeoxyglucose F18 2Etoposide 2temsirolimus 1sargramostim 1sacituzumab govitecan 1regorafenib 1pentetreotide 1pazopanib 1molibresib 1etoposide phosphate 1etirinotecan pegol 1entinostat 1durvalumab 1cc-486 1budigalimab 1berzosertib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × sacituzumab govitecan × CNS × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡